Randomised Controlled Trials (RCTs), particularly Phase III clinical trials, have long been considered the gold standard in medical research. They provide the foundational data required for regulatory approval, demonstrating that a new therapy is both safe and efficacious under strictly controlled conditions. However, the journey of a pharmaceutical product does not end with regulatory approval. In fact, understanding how a treatment performs in the general population begins only after it enters the market. This is where Real World Evidence Studies become indispensable.